The guidelines have been published in 2 journals: Breast and Annals of Oncology.
The latest international consensus guidelines for the management of advanced were published online September 18 in the Annals of Oncology and September 20 in the Breast.
The advanced breast cancer 2 (ABC2) guidelines urge more research and clinical trials into treatment for advanced disease, and describe advanced breast cancer patients as a "historically neglected population."
In particular, the guidelines note, more research is needed to find the best treatments for patients with breast cancer that has spread to the liver, pleural cavity, or the skin; patients with HER2-positive advanced breast cancer who relapse during or shortly after adjuvant treatment with ; patients with stage IV disease; and men with advanced breast cancer who require treatment with aromatase inhibitors, such as , , and letrozole.
Link to the report on Medscape: http://bit.ly/1riuURB
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More